DATTA; Sandip K.

Patent Applications and Registrations

Patent applications and USPTO patent grants for DATTA; Sandip K..The latest application filed is for "use of gram negative species to treat atopic dermatitis".

Company Profile

11.10.16

DATTA; Sandip K. - Bethesda MD

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20210169943 - MYLES; Ian Antheni ; et al.	2021-06-10
Use of gram negative species to treat atopic dermatitis Grant 10,980,846 - Myles , et al. April 20, 2	2021-04-20
Use of gram negative species to treat atopic dermatitis Grant 10,946,049 - Myles , et al. March 16, 2	2021-03-16
Use of gram negative species to treat atopic dermatitis Grant 10,946,048 - Myles , et al. March 16, 2	2021-03-16
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20200254029 - Kind Code	2020-08-13
Use of gram negative species to treat atopic dermatitis Grant 10,682,379 - Myles , et al.	2020-06-16
Use of gram negative species to treat atopic dermatitis Grant 10,668,114 - Myles , et al.	2020-06-02
Use of gram negative species to treat atopic dermatitis Grant 10,653,727 - Myles , et al.	2020-05-19
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20190381112 - MYLES; Ian Antheni ; et al.	2019-12-19
Use of gram negative species to treat atopic dermatitis Grant 10,500,238 - Myles , et al. Dec	2019-12-10
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20190343895 - MYLES; Ian Antheni ; et al.	2019-11-14
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20190343896 - MYLES; Ian Antheni ; et al.	2019-11-14
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20190192580 - MYLES; Ian Antheni ; et al.	2019-06-27
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20190175667 - MYLES; Ian Antheni ; et al.	2019-06-13
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20190167735 - MYLES; Ian Antheni ; et al.	2019-06-06
Use of gram negative species to treat atopic dermatitis Grant 10,293,005 - Myles , et al.	2019-05-21
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20190142874 - MYLES; Ian Antheni ; et al.	2019-05-16
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20190142873 - MYLES; Ian Antheni ; et al.	2019-05-16
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20190076486 - MYLES; Ian Antheni ; et al.	2019-03-14
Use of gram negative species to treat atopic dermatitis Grant 10,206,957 - Myles , et al. Feb	2019-02-19
Use of gram negative species to treat atopic dermatitis Grant 10,195,236 - Myles , et al. Fe	2019-02-05
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20180360891 - MYLES; Ian Antheni ; et al.	2018-12-20
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20180296612 - MYLES; Ian Antheni ; et al.	2018-10-18
Use Of Gram Negative Species To Treat Atopic Dermatitis App 20180214495 - MYLES; Ian Antheni ; et al.	2018-08-02
Compositions Containing Purine and Pyrimidine Nucleosides, Peptides, and Manganese and Their Uses App 20140314810 - Daly; Michael ; et al.	2014-10-23

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.